Auris Medical Holding Ltd (EARS)

0.88 -0.02  -2.21% NASDAQ Jul 13, 10:57 Delayed 2m USD
View Full Chart
Price Chart
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.aurismedical.com
  • Investor Relations URL: http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-IRHome
  • HQ State/Province: N/A
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Value
  • Next Earnings Release: N/A
  • Last Earnings Release: Mar. 14, 2018
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Auris Medical Holding Ltd is a clinical-stage biopharmaceutical company. The company develops novel products for the treatment of inner ear disorders. It has two projects in advanced clinical development Keyzilen for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. It is developing Keyzilen for the treatment of acute inner ear (peripheral) tinnitus following traumatic cochlear injury or otitis media (middle ear infection). Keyzilen contains Esketamine hydrochloride, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, formulated in a biocompatible and fully biodegradable gel. It is also developing AM-111 for the treatment of acute inner ear (sensorineural) hearing loss (ASNHL).

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.